View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024 VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) provides the following update: Dear shareholders, We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona Biochem’s path forward. AGM Last week, during our Annual General Meeting (AGM), we successfully gained another year of backing for our management team. Although it's common for many shareholders to abstain from voting, we're pleased to report that we'...

 PRESS RELEASE

Sirona Biochem Announces Close of Private Placement

Sirona Biochem Announces Close of Private Placement VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Vancouver, British Columbia – April 4, 2024 – . (TSX-V: SBM) (Frankfurt: ZSB) (“Sirona”) has closed its private placement (Private Placement”) for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the “Units”) at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of i...

 PRESS RELEASE

Sirona Biochem Announces 2023 Annual Meeting Results

Sirona Biochem Announces 2023 Annual Meeting Results VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in person and by proxy at the Meeting was 26,722,196, representing 10.52% of Sirona's issued and outstanding Common Shares. All matters put forward to shareholders for consideration and approval, as set out in the ...

 PRESS RELEASE

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Agin...

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations VANCOUVER, British Columbia, March 13, 2024 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions. The chose...

 PRESS RELEASE

Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim™...

Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim™ in Early 2025 VANCOUVER, British Columbia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF), also known as Sirona, is excited to share a new milestone in its journey. A recent exclusive video interview featuring Dr. Geraldine Deliencourt-Godefroy, Sirona's Chief Scientific Officer, has been released by the Investing News Network. In this interview, Dr. Deliencourt-Godefroy unveils Sirona's ambitious plans to introduce its innovative anti-aging product, GlycoProteMimTM, to t...

 PRESS RELEASE

Sirona Biochem Provides Update on Loan

Sirona Biochem Provides Update on Loan VANCOUVER, British Columbia, Feb. 15, 2024 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) announce that, further to its news release on January 29, 2024, it has entered into an amendment to the demand grid promissory note dated September 22, 2023 (the “Amended Note”) with 0906462 B.C. Ltd. (the “Lender”). The Amended Note evidences a loan in the aggregate principal amount of up to $1,000,000 (the “Loan”). Pursuant to the terms and conditions of the Amended Note: (a)   the Loan is repayable on demand by the L...

 PRESS RELEASE

Sirona Biochem Engages Global Beauty Consulting

Sirona Biochem Engages Global Beauty Consulting VANCOUVER, British Columbia, Feb. 15, 2024 (GLOBE NEWSWIRE) -- (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) has announced its partnership with Global Beauty Consulting – Cosmetics Laboratory (GBC), under the leadership of CEO Gaël Boutry, a distinguished French formulator. GBC is currently developing an exclusive premium formulation for GlycoProteMimTM in anticipation of its launch in the first quarter of 2025. GBC has a history of working with Sirona Biochem on the formulation of TFC-1067 for clinical development. This...

 PRESS RELEASE

Sirona Biochem Announces Loan

Sirona Biochem Announces Loan VANCOUVER, British Columbia, Jan. 29, 2024 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) announced that it has entered into a demand grid promissory note (the “Note”) with 0906462 B.C. Ltd. (the “Lender”) for a loan in the aggregate principal amount of up to $1,000,000 (the “Loan”). Pursuant to the terms and conditions of the Note: (a) the Loan is repayable on demand by the Lender;   (b) the Loan bears interest at a rate of 12% per annum, calculated yearly not in advance; and   (c) the Company has agreed to, subject to...

 PRESS RELEASE

Sirona Biochem Initiates Private Placement

Sirona Biochem Initiates Private Placement VANCOUVER, British Columbia, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V:SBM) (FSE: ZSB) (OTC: SRBCF) (the "Company") is pleased to announce a non-brokered private placement of up to 10,000,000 units of the Company at a price of $0.10 CAD per Unit (a "Unit") for gross proceeds of up to CAD$1,000,000 (the "Private Placement"). Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of is...

 PRESS RELEASE

CORRECTION -- Sirona Biochem Corporate Update January 2024

CORRECTION -- Sirona Biochem Corporate Update January 2024 VANCOUVER, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF), please note that in the 8th paragraph of the letter, the company plans to launch its first product early in the 1st quarter of 2025, not the 1st quarter of 2024 as previously stated. The corrected release follows: Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides the following update: Dear shareholders, We are pleased ...

 PRESS RELEASE

Sirona Biochem Corporate Update January 2024

Sirona Biochem Corporate Update January 2024 VANCOUVER, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides the following update: Dear shareholders, We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona Biochem's path forward. Trademark of TFC-1326 as GlycoProteMim We recently trademarked TFC-1326 as GlycoProteMimTM. This branding decision aims to distinguish our anti-aging active ingredient in a competitive...

 PRESS RELEASE

Sirona Biochem Launches Cosmetics Subsidiary- Sirona Laboratories™

Sirona Biochem Launches Cosmetics Subsidiary- Sirona Laboratories™ VANCOUVER, Canada, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is proud to introduce Sirona LaboratoriesTM - a wholly-owned subsidiary dedicated to maximizing the commercial potential of its breakthrough anti-aging skincare ingredient, GlycoProteMimTM. Dr. Howard Verrico, CEO and founder of Sirona Biochem, expressed his enthusiasm for the major milestone, stating that the establishment of Sirona Laboratories is meant to not just shape the future of the company, but to revolu...

 PRESS RELEASE

Sirona Biochem Initiates GlycoProteMim™ Trademark for Anti-Aging Molec...

Sirona Biochem Initiates GlycoProteMim™ Trademark for Anti-Aging Molecule TFC-1326 VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF), is making a strategic move in the world of advanced skincare solutions. Today, the company announces the trademarking of its groundbreaking anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim™. This pivotal decision marks a significant milestone in Sirona Biochem's mission to bring forth a new era of skincare innovation. The trademarking of GlycoProteMim™, filed with the In...

 PRESS RELEASE

Sirona Biochem Announces Change of Auditor

Sirona Biochem Announces Change of Auditor VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC:SRBCF) (the “Company") announces that it has changed its auditors from DeVisser Gray LLP (the “Former Auditor”) Davidson and Company (the “Successor Auditor”) effective October 25, 2023 and the board of directors of the Company appointed the Successor Auditor as the Company’s auditor effective October 25, 2023 until the next Annual General Meeting of the Company. There were no reservations in the Former Auditor’s audit reports for t...

 PRESS RELEASE

Sirona Biochem Announces Payment of Convertible Debenture Interests in...

Sirona Biochem Announces Payment of Convertible Debenture Interests in Shares NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES VANCOUVER, British Columbia, Oct. 20, 2023 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) announces that pursuant to the 12% unsecured, convertible debentures in the principal amount of $1,500,000 (the “Debentures”) previously issued on April 20, 2023, the Company will issue common shares in the capital of the Company (the “Common Shares”) in satisfaction of interest payments on the outstanding Debentures (...

 PRESS RELEASE

Sirona Biochem Initiates Significant Corporate Changes

Sirona Biochem Initiates Significant Corporate Changes VANCOUVER, British Columbia, June 15, 2022 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to inform about several significant corporate changes currently in preparation: Now that Sirona Biochem has closed an the next steps for sustainable and rapid growth of the company are initiated. The Board has begun a strategic review of every facet of the company including management, organizational structure, project pipeline, financial position and the exchanges on which the Sirona shares are listed. ...

 PRESS RELEASE

Sirona Biochem Announces Exclusive Global Licensing Agreement with All...

Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics Licenses Revolutionary Skin Care Compound TFC-1067 VANCOUVER, British Columbia, June 13, 2022 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for and related family of compound...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...

New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch